Idiopathic Pulmonary Fibrosis | Unmet Need | US/EU | 2023
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder associated with progressive inflammation and/or fibrosis of the lung tissue. The leading cause of the disorder is unknown. Individuals experience dyspnea and lung complications, which eventually cause respiratory failure. Boehringer Ingelheim’s Ofev and Roche / Genentech’s Esbriet are welcome options in the treatment armamentarium for IPF. Therapies that can further delay or reverse the disease’s progression, preserve lung function, and prolong survival are sorely needed. The diverse IPF pipeline comprises novel classes including prostacyclin vasodilators, CTGF inhibitors, ROCK 2 inhibitors, PDE4B inhibitors, Galectin-3 inhibitors, and agents targeting the LPA-1 receptor. In this report, we assess the clinical and commercial opportunities remaining in the IPF space through a comprehensive analysis of surveyed pulmonologists’ treatment drivers and goals and their perception of the performance of key current therapies against these goals.
QUESTIONS ANSWERED
- What are the treatment drivers and goals for IPF?
- Which drug attributes are key influences, which have limited impact, and which are hidden opportunities?
- How do current therapies such as Ofev and Esbriet perform on key treatment drivers and goals for IPF?
- What are the key opportunities for drug development in IPF? Where do surveyed pulmonologists perceive the largest gaps in the treatment of IPF?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European pulmonologists for a hypothetical new IPF drug?
PRODUCT DESCRIPTION
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, France, Germany, United Kingdom
Primary research: Survey of 61 U.S. and 31 European pulmonologists fielded in March 2023
Key companies: Roche, Boehringer Ingelheim, FibroGen
Key drugs: Esbriet, Ofev, prednisone
